Publication in Blood Advances featuring Toyosi Odenike and Wendy Stock as part of the BEAT-AML initiative! ashpublications.org/bloodadvances/…

On MDS Awareness Day, spread the word: most cases of MDS, or Myelodysplastic Syndromes, have an unknown cause. Find out more about possible causes here: aamds.org/mds/causes

New publication📝 ELN-refined Beat-AML risk stratification for older patients with newly diagnosed AML were published in Blood Advances by Fieke Hoff. Read more: loom.ly/Y8Ysjf0 #leusm #MedNews #MedEd

FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. fda.gov/drugs/resource… #OCENewsBurst

Looking forward to seeing all the Beat AML innovative trials this weekend! #ASH24 👇

Exciting update on the Phase 2 AUGMENT trial showing durable and meaningful response with revumenib in patients with heavily pretreated R/R KMT2Ar AML #ASH24

Long-term follow-up of the COMMANDS trial shows that Luspatercept remains superior to ESA at >1 and >1.5 years with 30% of the patients who continue to respond. Interestingly, patients with EPO <200 had a 2.3x greater response rate #ASH2024

Best part of #ASH24 is to catch up with friends Yazan Madanat, MD Naveen Premnath UTSW Simmons Cancer Center UT Southwestern Medical Center

Important study highlighting that early MRD- is associated with better outcome in patients treated with IC, and that intermediate/adverse-risk AML patients achieving MRD- after induction still need to proceed to HCT

new work from the BEAT AML study featuring Toyosi Odenike Wendy Stock as co-authors! pubmed.ncbi.nlm.nih.gov/40180903/

The mutation profile of older AML patients is different from that of younger patients with a very high prevalence of high risk mutations. However, almost 50% present with a potentially targeted mutation Blood Cancer Journal Dr. Uma Borate: Associate Professor Yazan Madanat, MD pubmed.ncbi.nlm.nih.gov/40180903/

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions ashpublications.org/blood/article-… Key slide 👇🏽 important to be aware of while managing lymphoid and #myeloid_neoplasms #leusm

FLT3-ITD MRD can identify which patients benefit from gilteritinib maintenance. ow.ly/B79T50VPLu4 #clinicaltrialsandobservations #myeloidneoplasia

Very good podcast by Dr. Johnson, a great story teller and physician who taught us much more than just medicine! UTSW Internal Medicine Chiefs UT Southwestern Medical Center

Wow — top line VERONA results are negative — no advantage to AZA + VEN compared to AZA alone for higher-risk #MDSsm. AZA or DAC alone remain the standard for HR-MDS. So disappointing😢 🎗️🩸news.abbvie.com/2025-06-16-Abb…

I've long been fascinated by the role of iron chelation- and its disordered metabolism- in MDS, particularly in the context of transplantation. This effort led by Fieke Hoff Steven Pavletic M.D., Ph.D. and Ed Schulz emerged from that curiosity. doi.org/10.1016/j.blre…

Pleased to see our work looking at the impact of cytokine derived therapies / steroids on hematologic progression in #VEXAS led by Benjamin Turturice Peter Grayson now published in Annals of the Rheumatic Diseases. sciencedirect.com/science/articl… Bhavisha Patel Fernanda Gutierrez-Rodrigues Neal S Young M.D.

Please check our recent Seminar review in The Lancet discussing the biology of #ALL and evolution of treatment for both pediatric and adult patients MD Anderson Cancer Center #Leukemia thelancet.com/journals/lance… #leusm

Review on the management of LR-MDS with novel agents including imetelstat. Thanks for collaborating! Yazan Madanat, MD Amer Zeidan MBBS,MHS ‏عامر زيدان Stephen Chung

Excited to see these finally published! American College of Rheumatology guidance statement for diagnosis and management of #VEXAS. A major international effort! acrjournals.onlinelibrary.wiley.com/doi/10.1002/ar…